Multicenter Study
doi: 10.3324/haematol.11288.
FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Affiliations
- PMID: 17650444
- DOI: 10.3324/haematol.11288
Item in Clipboard
Multicenter Study
FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Haematologica.
2007 Aug.
Free article
Abstract
We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.
Similar articles
-
Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma.Blood. 2005 May 1;105(9):3428-33. doi: 10.1182/blood-2004-06-2490. Epub 2005 Jan 6. Blood. 2005. PMID: 15637137
-
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.J Chemother. 2007 Jun;19(3):315-21. doi: 10.1179/joc.2007.19.3.315. J Chemother. 2007. PMID: 17594928 Clinical Trial.
-
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.Haematologica. 2007 Jul;92(7):998-9. doi: 10.3324/haematol.10327. Haematologica. 2007. PMID: 17606457
-
Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Semin Oncol. 2002. PMID: 11842390 Review.
-
Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.Health Technol Assess. 2012;16(37):1-253, iii-iv. doi: 10.3310/hta16370. Health Technol Assess. 2012. PMID: 23021127 Review.
Cited by
-
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics.MAbs. 2013 Nov-Dec;5(6):826-37. doi: 10.4161/mabs.26008. Epub 2013 Aug 8. MAbs. 2013. PMID: 23933992 Free PMC article. Review.
-
Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.Cancer. 2011 Jun 1;117(11):2442-51. doi: 10.1002/cncr.25792. Epub 2010 Dec 14. Cancer. 2011. PMID: 24048792 Free PMC article. Clinical Trial.
-
Host genetics in follicular lymphoma.Best Pract Res Clin Haematol. 2011 Jun;24(2):121-34. doi: 10.1016/j.beha.2011.02.004. Epub 2011 May 5. Best Pract Res Clin Haematol. 2011. PMID: 21658613 Free PMC article. Review.
-
Rituximab for the treatment of patients with chronic lymphocytic leukemia.Cancer Manag Res. 2010 Mar 11;2:71-81. doi: 10.2147/cmar.s5621. Cancer Manag Res. 2010. PMID: 21188098 Free PMC article.
-
The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients.Oncol Lett. 2016 May;11(5):3332-3336. doi: 10.3892/ol.2016.4402. Epub 2016 Apr 1. Oncol Lett. 2016. PMID: 27123112 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
